Monitoring inhaler usage in patients with asthma and COPD with real-time data just got easier with the arrival of the FDA-approved Hailie Smartinhaler for usage with AstraZeneca’s Airsupra and Breztri inhalation devices.
Airsupra serves as a rescue inhaler for asthma patients, while Breztri is a long-term inhaler used for reducing exacerbations in COPD patients.
The option to combine the Hailie Smartinhaler with these medications gives patients and clinicians real-time data and insights into medication usage patterns and inhaler technique feedback.
Bill McCann, MD, MBA, vice president and chief medical officer of Allergy Partners, P.A., said the approval of the technology will help provide more personalized care and improve patient quality and outcomes.
“The combination of the Hailie Smartinhaler with Airsupra and Breztri devices represents a leap forward in our ability to treat and manage asthma and COPD,” he said. “This integration allows for a more nuanced understanding of patient needs and the ability to adjust treatments in real-time, which is invaluable in achieving optimal patient outcomes.”
